TY - JOUR
T1 - Variable CD52 expression in mature T cell and NK cell malignancies
T2 - Implications for alemtuzumab therapy
AU - Jiang, Liuyan
AU - Yuan, Constance M.
AU - Hubacheck, Julia
AU - Janik, John Edward
AU - Wilson, Wyndham
AU - Morris, John C.
AU - Jasper, Gregory A.
AU - Stetler-Stevenson, Maryalice
PY - 2009/4
Y1 - 2009/4
N2 - The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies. To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL). The level of CD52 expression was quantified using QuantiBRITE standard beads. The level of CD52 expression varied widely within each diagnostic category. All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92·3%), ATLL (94·1%) and CTCL (87·5%), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50%) and ENT/NKCL (25%). FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy. Further studies are necessary to determine if the level of CD52 expression correlates with response to therapy.
AB - The anti-CD52 antibody alemtuzumab has been explored as a novel targeted therapy in T cell malignancies. To assess the suitability of alemtuzumab therapy, we carried out a comprehensive study of CD52 expression using flow cytometry (FC) in 78 untreated patients diagnosed with mature T/natural killer (NK) cell neoplasms, including 34 adult T cell leukaemia/lymphomas (ATLL), two anaplastic large cell lymphomas (ALCL), three angioimmunoblastic T cell lymphomas (AITL), 16 cutaneous T cell lymphomas (CTCL), four extra-nodal T/NK cell lymphomas (ENT/NKCL), four hepatosplenic T cell lymphomas (HSTCL), 13 peripheral T cell lymphomas, not otherwise specified (PTCL-NOS) and two T-prolymphocytic leukaemia (T-PLL). The level of CD52 expression was quantified using QuantiBRITE standard beads. The level of CD52 expression varied widely within each diagnostic category. All AITL, HSTCL and T-PLL cases were CD52-positive and the frequency of CD52 expression was high in PTCL-NOS (92·3%), ATLL (94·1%) and CTCL (87·5%), implying a rational role for alemtuzumab in the treatment of these diseases; however, CD52 expression was low in ALCL (50%) and ENT/NKCL (25%). FC testing for cell surface expression of CD52 is indicated in patients with T/NK cell malignancies being considered for alemtuzumab therapy. Further studies are necessary to determine if the level of CD52 expression correlates with response to therapy.
KW - Alemtuzumab
KW - CD52
KW - Flow cytometry
KW - NK cell lymphoma
KW - T cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=63149129736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63149129736&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2009.07606.x
DO - 10.1111/j.1365-2141.2009.07606.x
M3 - Article
C2 - 19236377
AN - SCOPUS:63149129736
SN - 0007-1048
VL - 145
SP - 173
EP - 179
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 2
ER -